.Attribute Medication, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA study, after a mean consequence of 11 months, individuals along with metastatic intestinal tumors that obtained biomarker-matched treatments based upon distributing tumor DNA profiling showed a better clinical benefit than those receiving unrivaled therapy.